Watchful waiting, ADT groups analyzed
A subsequent subset analysis for each treatment group found that among men in the watchful-waiting group, prostate cancer-specific mortality was associated with any comorbidity (Charlson index scores 1, 2, or 3+) versus no comorbidity (Charlson index score 0). However, this association disappeared when statistically adjusted for patient and tumor characteristics. A subgroup analysis of data for patients in the androgen deprivation therapy group found that a Charlson comorbidity index of ≥3 was associated with a modest 1.10 hazard ratio for prostate cancer-specific mortality compared to patients without comorbidities, both before and after adjusting for patient and tumor characteristics (p=.004 and .014, respectively).
It is possible that cause of death misclassifications in the Swedish deaths registry, difficulty detecting relevant comorbid conditions, or early deaths from non-cancer causes might have affected the findings, the authors acknowledged.
More from Urology Times:
Subscribe to Urology Times to get monthly news from the leading news source for urologists.